ClinicalTrials.gg
CompletedNCT06054425Updated May 14, 2024

A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults

A Phase 1 interventional study of Risankizumab in Healthy Volunteers, sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective of this study is to assess the bioavailability of risankizumab liquid vial manufactured with the new process (CMC3) relative to the current process (CMC2).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Risankizumab
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) >= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal at the time of screening and upon initial confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead (ECG).
  • Body weight less than 100.00 kg at Screening and upon initial confinement.

Exclusion criteria

Exclusion Criteria:

  • History of any illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
  • Previous exposure to any anti-interleukin (IL)-12/23 or anti-IL-23 treatment for at least one year prior to Screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Arm 1

    Participants will receive risankizumab manufactured with using the current process (CMC2).

    Drug: Risankizumab

  • Active comparator
    Arm 2

    Participants will receive risankizumab manufactured with using the new process (CMC3).

    Drug: Risankizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax)

    Cmax will be assessed.

    Time frame: Up to Day 131

  2. Time to Cmax (Tmax)

    Tmax will be assessed.

    Time frame: Up to Day 131

  3. Apparent Terminal Phase Elimination Rate Constant (β)

    Apparent terminal phase elimination rate constant (β) will be assessed.

    Time frame: Up to Day 131

  4. Terminal Phase Elimination Half-life (t1/2)

    Terminal phase elimination half-life (t1/2) will be assessed.

    Time frame: Up to Day 131

  5. Area Under the Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUC0-t)

    AUC0-t will be assessed.

    Time frame: Up to Day 131

  6. AUC from Time 0 to Infinity (AUC0-inf)

    AUC0-inf will be assessed.

    Time frame: Up to Day 131

  7. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Baseline to Day 141

07

Study locations

3 sites
  • Anaheim Clinical Trials LLC /ID# 260740
    Anaheim, California 92801-2658, United States
  • Clinical Pharmacology of Miami /ID# 260800
    Miami, Florida 33014, United States
  • Acpru /Id# 260864
    Grayslake, Illinois 60030, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in May 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2023
First posted
Sep 26, 2023
StartActual
Nov 20, 2023
Primary completionActual
May 6, 2024
CompletionActual
May 6, 2024
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06054425
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Nov 20, 2023
Primary completion
May 6, 2024
Completion
May 6, 2024
Last update
May 14, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion